Arvinas, Inc. develops targeted protein degradation medicines through its PROTAC protein degrader platform. Company updates center on VEPPANU (vepdegestrant), developed with Pfizer and approved by the FDA for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine-based therapy, as well as regulatory, clinical, and corporate milestones tied to that program.
Arvinas news also covers investigational PROTAC degraders across oncology, neurology, and neuromuscular disease, including ARV-102 for LRRK2-driven neurodegenerative disorders, ARV-806 for KRAS G12D-mutated cancers, ARV-393 for BCL6-driven lymphoma, and ARV-027 as a polyQ-AR degrader. Recurring items include clinical data presentations, financial results, corporate updates, investor conferences, and governance changes.
Arvinas (Nasdaq: ARVN) presented final Phase 1 data showing exploratory eye-movement improvements with investigational ARV-102 in patients with Parkinson’s disease. The trial evaluated oral doses of 20 mg to 80 mg and placebo for 28 days in 24 patients. Dose-dependent increases in eye-movement amplitude compared with placebo reflected less severe hypometria, or movements falling short of their target.
Biomarkers linked to cellular waste processing and neuroinflammation decreased, while markers of synaptic integrity and axonal guidance increased. Reductions in cerebrospinal fluid LRRK2 protein were associated with improved eye-movement function and changes in these pathway biomarkers. The study was not designed to assess clinical efficacy. Arvinas said the findings support further clinical evaluation of ARV-102. Final results were presented at the 2026 International Congress of Parkinson’s Disease and Movement Disorders in Seoul.
Arvinas (ARVN) will present Phase 1 ARV-102 biomarker data at the International Congress of Parkinson’s Disease and Movement Disorders on October 7, 2026. The data concern participants with Parkinson’s disease and will be shared in a late-breaking oral presentation and an online e-poster. The presentation, titled “Phase 1 Study of ARV-102, a PROTAC LRRK2 Degrader, in Parkinson’s Disease: Oculomotor and Biomarker Data,” covers eye-movement and biomarker data. The congress takes place October 4–8, 2026, in Seoul, Korea.
ARV-102 is an investigational oral drug designed to cross the blood-brain barrier and degrade LRRK2, a protein implicated in Parkinson’s disease and progressive supranuclear palsy. It has been evaluated in Phase 1 trials in healthy volunteers and patients with Parkinson’s disease. The announcement schedules the presentations rather than reporting their clinical findings.
Arvinas (Nasdaq: ARVN) granted equity inducement awards to one newly hired employee, effective September 28, 2026.
The awards comprise an option to purchase 64,766 common shares and 42,388 restricted stock units. The option has a 10-year term and an exercise price of $7.51 per share, equal to the stock’s closing price on the grant date. Both awards vest over four years, subject to continued service as an employee or other service provider through the applicable vesting dates. They were granted under Nasdaq Listing Rule 5635(c)(4), outside Arvinas’ stock incentive plan.
Arvinas (ARVN) has dosed the first patient in a Phase 1/2 trial of its immuno-oncology candidate ARV-6723.
The oral drug is designed to degrade HPK1, a protein that restrains immune activation. The global, multicenter ARV-6723-101 study will assess safety, how the drug moves through and affects the body, and preliminary antitumor activity in adults with advanced solid tumors. It begins with ARV-6723 alone and will later assess a combination with pembrolizumab. The initial group is enrolling patients previously treated with an immune checkpoint inhibitor who have no suitable standard treatment options.
In preclinical studies, ARV-6723 showed selective HPK1 degradation, enhanced immune activity and antitumor activity alone and with an immune checkpoint inhibitor. In seven models, it showed single-agent activity where neither an HPK1 inhibitor nor anti-PD-1 therapy showed benefit. Whether HPK1 degradation produces antitumor effects in patients remains to be tested.
Arvinas (ARVN) will participate in fireside chats at three September 2026 healthcare investor conferences. Management is scheduled for the Wells Fargo Healthcare Conference on September 8 at 1:30 p.m. ET, the Cantor Global Healthcare Conference on September 10 at 2:10 p.m. ET, and the Morgan Stanley Annual Global Healthcare Conference on September 16 at 9:15 a.m. ET.
Live webcasts for each appearance will be available and later accessible in the Events and Presentations section of the company’s website.
Arvinas (Nasdaq: ARVN) granted an inducement award of 45,696 restricted stock units (RSUs) to one newly hired employee, effective August 31, 2026, under Nasdaq Listing Rule 5635(c)(4). The award was made outside the company’s stock incentive plan and will vest in full on the first anniversary of the grant date, subject to the employee’s continued service with Arvinas.
Arvinas is a clinical-stage biotechnology company developing targeted protein degradation therapies via its PROTAC platform and is advancing multiple investigational drugs in oncology and neurological indications.
Arvinas (Nasdaq: ARVN) reported second quarter 2026 results highlighted by FDA approval of VEPPANU, the first-ever approved PROTAC degrader, for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after at least one line of endocrine therapy. VEPPANU was subsequently out-licensed to Rigel Pharmaceuticals for exclusive global development, manufacturing, and commercialization and was added as a Category 2A option in NCCN breast cancer guidelines.
Second quarter revenue rose to $249.7 million from $22.4 million, driven by Pfizer collaboration revenue, a $50 million approval milestone and $62.5 million from the Rigel license. GAAP R&D fell to $52.6 million and GAAP G&A to $24.0 million. Cash and investments totaled $567.9 million, with funding runway projected into 2H 2028. The company advanced multiple PROTAC programs, with initial data from ARV-393, ARV-102, ARV-027 and ARV-806 and first-in-human dosing of ARV-6723 expected over the next 12–24 months.
Arvinas (Nasdaq: ARVN) will host a live webcast on Tuesday, August 4, 2026 at 8:00 a.m. ET to review its second quarter 2026 financial results and provide a corporate update. The event will be accessible via the “Events and Presentations” section on the Arvinas investor webpage, with a replay available afterward.
Arvinas is a biotechnology company focused on targeted protein degradation through its PROTAC protein degrader platform. The company, which co-developed the first FDA‑approved PROTAC with Pfizer, is advancing multiple investigational drugs for neurodegenerative disorders, mutated cancers, relapsed/refractory non-Hodgkin lymphoma, and skeletal muscle conditions.
Arvinas (Nasdaq: ARVN) joined the Michael J. Fox Foundation–supported LITE and PPMI programs to advance ARV-102, its investigational, orally bioavailable, brain-penetrant PROTAC targeting LRRK2 for potential treatment of Parkinson’s disease and PSP.
These collaborations provide shared data, biomarker infrastructure, and expert networks to inform translational and clinical strategies for ARV-102.
Arvinas (Nasdaq: ARVN), a clinical-stage biotech focused on targeted protein degradation, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, at 9:55 a.m. ET. A live audio webcast will be accessible via the company’s investor website.